cancers Review miRNAs and lncRNAs as Novel Therapeutic Targets to Improve Cancer Immunotherapy Maria Teresa Di Martino 1,*,† , Caterina Riillo 1,† , Francesca Scionti 2, Katia Grillone 1 , Nicoletta Polerà 1, Daniele Caracciolo 1, Mariamena Arbitrio 3, Pierosandro Tagliaferri 1 and Pierfrancesco Tassone 1 1 Department of Clinical and Experimental Medicine, Magna Graecia University of Catanzaro, 88100 Catanzaro, Italy;
[email protected] (C.R.);
[email protected] (K.G.);
[email protected] (N.P.);
[email protected] (D.C.);
[email protected] (P.T.);
[email protected] (P.T.) 2 Institute of Research and Biomedical Innovation (IRIB), Italian National Council (CNR), 98164 Messina, Italy;
[email protected] 3 Institute of Research and Biomedical Innovation (IRIB), Italian National Council (CNR), 88100 Catanzaro, Italy;
[email protected] * Correspondence:
[email protected] † These authors contributed equally. Simple Summary: Cancer onset and progression are promoted by high deregulation of the immune system. Recently, major advances in molecular and clinical cancer immunology have been achieved, offering new agents for the treatment of common tumors, often with astonishing benefits in terms of prolonged survival and even cure. Unfortunately, most tumors are still resistant to current immune therapy approaches, and basic knowledge of the resistance mechanisms is eagerly awaited. We Citation: Di Martino, M.T.; Riillo, C.; focused our attention on noncoding RNAs, a class of RNA that regulates many biological processes Scionti, F.; Grillone, K.; Polerà, N.; by targeting selectively crucial molecular pathways and that, recently, had their role in cancer cell Caracciolo, D.; Arbitrio, M.; immune escape and modulation of the tumor microenvironment identified, suggesting their function Tagliaferri, P.; Tassone, P.